Arrowhead Pharmaceuticals announced the presentation of new preclinical data on its expanding pipeline of RNA interference therapeutics for cardiometabolic diseases, including ARO-ANG3, which targets
angiopoietin-like protein 3, and ARO-APOC3, which targets apolipoprotein C-III.
Other medications belonging to the classes of antisense oligonucleotides are those that inhibit the production of the
angiopoietin-like protein 3 (ANGPTL3) enzyme.
The product is an investigational monoclonal antibody to
angiopoietin-like protein 3 (ANGPTL3).
Mabuchi et al., "Association of
angiopoietin-like protein 3 with hepatic triglyceride lipase and lipoprotein lipase activities in human plasma," Annals of Clinical Biochemistry, vol.
Maranghi, "The
angiopoietin-like protein 3: a hepatokine with expanding role in metabolism," Current Opinion in Lipidology, vol.